ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
AstraZeneca
AstraZeneca
Tempest Therapeutics
Incyte Corporation
PharmaMar
Exelixis
Inspirna, Inc.
Lindis Bloodcare GmbH
Compugen Ltd
Acepodia Biotech, Inc.
Vincerx Pharma, Inc.
Vincerx Pharma, Inc.
Mundipharma Research Limited
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Xencor, Inc.
Prelude Therapeutics
Arcus Biosciences, Inc.
NextCure, Inc.
Corvus Pharmaceuticals, Inc.
Genmab
Xencor, Inc.
Xencor, Inc.
Incyte Corporation
Incyte Corporation
MacroGenics
Incyte Corporation
Seagen Inc.
Gilead Sciences
Eisai Inc.
Seagen Inc.
Ciusss de L'Est de l'Île de Montréal
Lumos Pharma
Abramson Cancer Center at Penn Medicine
Oncology Institute of Southern Switzerland
Memorial Sloan Kettering Cancer Center
Wake Forest University Health Sciences
Amgen
Santa Maria Biotherapeutics
University of Southern California
BIND Therapeutics
Rutgers, The State University of New Jersey
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sanofi
National Cancer Institute (NCI)
National Cancer Institute (NCI)